Dimensional Fund Advisors LP Sells 28,243 Shares of Electromed, Inc. (NYSE:ELMD)

Dimensional Fund Advisors LP reduced its stake in shares of Electromed, Inc. (NYSE:ELMD - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,219 shares of the company's stock after selling 28,243 shares during the period. Dimensional Fund Advisors LP owned 2.96% of Electromed worth $7,394,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in Electromed during the fourth quarter valued at about $37,000. IFP Advisors Inc bought a new position in shares of Electromed in the fourth quarter worth about $59,000. Quantbot Technologies LP bought a new position in shares of Electromed in the fourth quarter worth about $99,000. Bailard Inc. bought a new position in shares of Electromed in the fourth quarter worth about $224,000. Finally, Jump Financial LLC bought a new position in shares of Electromed in the fourth quarter worth about $237,000. 40.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on ELMD. StockNews.com lowered Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley assumed coverage on Electromed in a research note on Thursday, February 20th. They set a "buy" rating and a $38.00 price target on the stock.

Electromed Stock Performance

NYSE ELMD traded up $1.43 during trading on Friday, reaching $20.98. 96,037 shares of the company traded hands, compared to its average volume of 71,213. The stock's 50 day moving average price is $23.17 and its two-hundred day moving average price is $27.27. The company has a market cap of $179.48 million, a price-to-earnings ratio of 27.99 and a beta of 0.46. Electromed, Inc. has a 1-year low of $13.74 and a 1-year high of $35.56.

Electromed declared that its Board of Directors has authorized a share buyback program on Monday, March 10th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued.

Insider Transactions at Electromed

In other Electromed news, Director Andrew Summers sold 50,751 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the transaction, the director now owns 65,714 shares of the company's stock, valued at approximately $1,793,992.20. This represents a 43.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathleen Skarvan sold 38,954 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $29.28, for a total value of $1,140,573.12. Following the transaction, the director now directly owns 32,622 shares in the company, valued at approximately $955,172.16. This represents a 54.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,978 shares of company stock valued at $3,542,996 in the last three months. 14.00% of the stock is owned by corporate insiders.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.